Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Amarantus BioScience Holdings, Inc. (AMBS)
New York City, NY, US
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +900.00% | +0.00% | +900.00% | -66.67% | -89.47% | -98.75% | -99.84% | +140,546.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+62.6% ★ Q1'23: +98.5% (vs Q1'22)
-
FCF margin FCF growth · Biotechnology: +16.2%-4,502.2% Q1'23: +625.4% (vs Q1'22)
-
EBIT margin Biotechnology: +0.0%-4,995.2% Q1'23: -4,080.5% (vs Q1'22)
-
ROIC Biotechnology: -16.1%— Q1'23: +3.7% (vs Q1'22)
-
Share dilution Biotechnology: -3.4%+24.6% Q1'23: +35.5% (vs Q1'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.22× Q1'23: -79.68× (vs Q1'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Amin Nathoo | 14.18M | 4.99% | — | 14.18M | — | 10.00 | HC, IN | OR PLACE OF ORGANIZATION | 2020-10-05 | ↗ |
| 2 | Anson Advisors Inc. | 14.18M | 4.99% | — | 14.18M | — | 10.00 | FI, CO | OR PLACE OF ORGANIZATION | 2020-10-05 | ↗ |
| 3 | Anson Funds Management LP | 14.18M | 4.99% | — | 14.18M | — | 10.00 | IA, PN | OR PLACE OF ORGANIZATION | 2020-10-05 | ↗ |
| 4 | Anson Management GP LLC | 14.18M | 4.99% | — | 14.18M | — | 10.00 | HC, OO | OR PLACE OF ORGANIZATION | 2020-10-05 | ↗ |
| 5 | Bruce R. Winson | 14.18M | 4.99% | — | 14.18M | — | 10.00 | HC, IN | OR PLACE OF ORGANIZATION | 2020-10-05 | ↗ |
| 6 | Dominion Capital LLC 452571126 | 14.18M | 4.99% | — | 14.18M | — | 14.18M | OO | — | 2020-10-05 | ↗ |
| 7 | Eliyahu Hassett | 14.18M | 4.99% | — | 14.18M | — | 14.18M | IN | — | 2020-10-09 | ↗ |
| 8 | Lorient Ventures Limited | 14.18M | 4.99% | — | 14.18M | — | 14.18M | OO | — | 2020-10-09 | ↗ |
| 9 | Mikhail Gurevich | 14.18M | 4.99% | — | 14.18M | — | 14.18M | HC, IN | — | 2020-10-05 | ↗ |
| 10 | Moez Kassam | 14.18M | 4.99% | — | 14.18M | — | 10.00 | HC, IN | OR PLACE OF ORGANIZATION | 2020-10-05 | ↗ |
| 11 | Master Fund, Ltd. | 1.91M | 9.99% | — | 1.91M | — | — | CO | Islands | 2015-12-29 | ↗ |
| 12 | Strategies LLC, Inc. | 1.91M | 9.99% | — | 1.91M | — | — | CO | Nevada | 2015-12-29 | ↗ |
| 13 | Winters | 1.91M | 9.99% | — | 1.91M | — | — | IN | States | 2015-12-29 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-05-12 | Flanigan Conn | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-02-23 | Flanigan Conn | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-02-01 | COMMISSIONG GERALD | Director / Officer | J-Other | A | Common Stock | 45,283 | 0.27 | 12.0K | 100,347 | — | ↗ |
| 2015-04-09 | FARRELL ROBERT EDWARD | Officer | P-Purchase | A | Common Stock | 200,000 | 0.05 | 10.0K | 333,333 | — | ↗ |
| 2015-04-08 | COMMISSIONG GERALD | Director / Officer | P-Purchase | A | Common Stock | 203,000 | 0.05 | 9.7K | 8,259,565 | — | ↗ |
| 2015-01-12 | Huffman Donald D | Director | A-Award | A | Option to Purchase Common Stock | 6,490,000 | 0.08 | 519.2K | 6,490,000 | — | ↗ |
| 2014-11-20 | COMMISSIONG GERALD | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.08 | 768.00 | 8,019,565 | — | ↗ |
| 2014-11-19 | FARRELL ROBERT EDWARD | Director / Officer | P-Purchase | A | Common Stock | 133,333 | 0.08 | 10.0K | 133,333 | — | ↗ |
| 2014-09-22 | COMMISSIONG GERALD | Director / Officer | A-Award | A | Options to Purchase Common Stock | 5,000,000 | 0.09 | 438.0K | 5,000,000 | — | ↗ |
| 2014-07-22 | Huffman Donald D | Director | — | D | Options to Purchase Common Stock | 200,000 | 0.15 | 29.2K | 0 | — | ↗ |
| 2014-03-31 | FARRELL ROBERT EDWARD | Officer | — | D | Options to Purchase Common Stock | 8,000,000 | 0.08 | 620.0K | 0 | — | ↗ |
| 2014-01-17 | COMMISSIONG GERALD | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 0.09 | 4.6K | 7,742,300 | — | ↗ |
| 2013-11-01 | COMMISSIONG GERALD | Officer | — | D | Series C Convertible Preferred Stock | 175,000 | 0.00 | — | 0 | — | ↗ |
| 2013-09-26 | COMMISSIONG GERALD | Officer | — | D | Warrants to Purchase Common Stock | 138,889 | 0.06 | 8.3K | 0 | — | ↗ |
| 2013-08-02 | COMMISSIONG GERALD | Officer | — | D | Common Stock | 0 | 0.00 | — | 7,889,565 | — | ↗ |
| 2013-04-30 | COMMISSIONG GERALD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 50,000 | 0.05 | 2.5K | 7,692,300 | — | ↗ |
| 2013-02-21 | COMMISSIONG GERALD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 50,000 | 0.07 | 3.6K | 7,642,300 | — | ↗ |
| 2013-02-05 | COMMISSIONG GERALD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,100 | 0.08 | 176.40 | 7,592,300 | — | ↗ |
| 2013-01-14 | COMMISSIONG GERALD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.09 | 1.4K | 7,542,300 | — | ↗ |
| 2013-01-11 | COMMISSIONG GERALD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.07 | 1.1K | 7,517,300 | — | ↗ |
| 2012-11-04 | COMMISSIONG GERALD | Director / Officer / 10% Owner | A-Award | A | 5% Convertible Preferred Stock | 500,000 | 1.50 | 750.0K | 48,531,829 | — | ↗ |
| 2012-07-15 | COMMISSIONG GERALD | Director / Officer / 10% Owner | A-Award | A | 5% Convertible Preferred Stock | 471,250 | 1.50 | 706.9K | 23,531,829 | — | ↗ |
| 2011-09-25 | COMMISSIONG GERALD | Officer | — | D | Option to Purchase Common Stock | 269,329 | 0.02 | 6.4K | 0 | — | ↗ |
| 2011-05-04 | COMMISSIONG GERALD | Director / Officer / 10% Owner | A-Award | A | Common Stock Options | 269,329 | 0.03 | 7.3K | 269,329 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aimee Boutcher | Director of Investor Relations | — | — |
| Brian E. Harvey | Chief Regulatory Advisor & Member of Board of Advisors | — | — |
| John Wesley Commissiong | Chief Scientific Officer, Director & Member of Scientific Advisory Board | — | — |
| Owen Garrick | Corporate Advisor | — | — |
| Ravi Kiron | Senior Vice President of Business Development | — | — |
| Robert Lewis Harris | Compliance Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMBS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
